European Journal of Cancer
Volume 41, Issue 17 , Pages 2630-2636 , November 2005

Fludarabine phosphate–CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: A dose-finding study

Received 24 November 2004 ,Revised 19 August 2005 ,Accepted 23 August 2005.

References 

  1. Soubeyran P, Eghbali H, Bonichon F, et al. Low-grade follicular lymphomas: analysis of 281 prognosis in a series of patients. Eur J Cancer. 1991;27:1606–1613
  2. Bastion Y, Berger F, Bryon PA, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol. 1991;2(Suppl. 2):123–129
  3. Soubeyran P, Eghbali H, Bonichon F, et al. Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol. 1988;13:91–98
  4. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Étude des Lymphomes Folliculaires. Groupe d’Étude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–1117
  5. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25:11–16
  6. Soubeyran P, Debled M, Tchen N, et al. Follicular lymphomas: a review of treatment modalities. Crit Rev Oncol Hematol. 2000;35:13–32
  7. Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin’s lymphoma. Ann Oncol. 1993;4:575–578
  8. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992;10:790–794
  9. Pigaditou A, Rohatiner AZ, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol. 1993;20:24–27
  10. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1996;14:514–519
  11. Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol. 1999;10:1191–1197
  12. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol. 2000;18:773–779
  13. Hagenbeek A, Eghbali H, Monfardini S, et al. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin’s lymphoma. Final analysis of a prospective randomized Phase III Intergroup Study in 381 patients. Blood. 2001;98:315a;[abstr 3501]
  14. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2448
  15. Koehl U, Li L, Nowak B. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross link removal. Proc Am Soc Cancer Research. 1997;38:2;[abstr 10]
  16. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999;94:2836–2843
  17. Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1998;16:41–47
  18. Unterhalt M, Herrmann R, Tiemann M, et al. Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group. Leukemia. 1996;10:836–843
  19. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin’s lymphoma. Ann Oncol. 1999;10:59–64
  20. Zaja F, Rogato A, Russo D, et al. Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin’s lymphomas. Eur J Haematol. 1997;59:327–328
  21. Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin’s lymphomas. Leuk Lymphoma. 1999;33:155–160
  22. Klasa R, Connors J, Gascoyne R, et al. CPF (cyclophosphamide, prednisone, fludarabine) in advanced stage previously untreated low grade and mantle cell lymphoma. Blood. 1997;90:[abstr 1527]
  23. Frewin R, Turner D, Tighe M, et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lympho-proliferative disorders. Br J Haematol. 1999;104:612–613
  24. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987–994
  25. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  27. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  28. Shuster JJ. Median follow up in clinical trials. J Clin Oncol. 1991;9:191–192
  29. Altman DG, de Stavola BL, Love SB, et al. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72:511–518
  30. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253
  31. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265
  32. Cazin B, Maloum K, Divine M, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts. Blood. 2002;100:206a;[abstr 773]
  33. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71–75
  34. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262–1268
  35. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with low-grade non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol. 1999;17:1574–1579
  36. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2001;19:4252–4258
  37. Oscier D, Orchard JA, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol J. 2001;2:316–321
  38. Czuczman M, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694–704
  39. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  40. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol. 2004;22:2654–2661

PII: S0959-8049(05)00723-9

doi: 10.1016/j.ejca.2005.08.021

European Journal of Cancer
Volume 41, Issue 17 , Pages 2630-2636 , November 2005

Article Tools

* Image Usage & Resolution